Drugs · Brain health technique
Anti-Amyloid Monoclonal Antibodies
Evidence grade: Context Dependent

FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™). These antibodies enhance immune-mediated clearance of amyloid from the brain, aiming to preserve cognitive function in early-stage disease.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Neuroprotective & Disease-modifying Therapies
- Evidence grade
- Context Dependent
- Strength of evidence
- Medium
- Effort
- Medium
- Time commitment
- High
How to practice Anti-Amyloid Monoclonal Antibodies
Indicated for early Alzheimer’s confirmed by amyloid PET and cognitive testing. Administered via IV infusion every 2–4 weeks in specialized centers. Requires MRI monitoring for ARIA and APOE genotyping. Benefits are disease-modifying but partial; not for late-stage disease or asymptomatic use. Best outcomes occur with early diagnosis and concurrent vascular/metabolic optimization.
The evidence behind Anti-Amyloid Monoclonal Antibodies
Anti-amyloid antibodies are lab-made immune proteins that latch onto clumps of amyloid. The antibodies help your brain's immune cells clear it away and may lower inflammation. Evidence that the antibodies reduce amyloid is strong. The main risk is ARIA (amyloid-related imaging abnormalities): brain swelling or tiny bleeds seen on scans. It's more likely in carriers of the APOE-ε4 gene variant.
Impact on brain health
Large late-stage trials show these drugs slow cognitive decline by roughly 25 to 35% compared with placebo. The trials enrolled people with early Alzheimer's confirmed by a scan, at the mild cognitive impairment or mild dementia stage. Evidence for benefit in how people actually feel and function is modest.
Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science
More Drugs techniques
Pair this with other habits from the same practice.

Evidence grade: Context Dependent
Antihypertensives
Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

Evidence grade: Context Dependent
GLP-1 Receptor Agonists
A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.

Evidence grade: Context Dependent
Lipid-Lowering Drugs
Therapies that reduce LDL cholesterol and vascular inflammation, including statins (atorvastatin, rosuvastatin, simvastatin), PCSK9 inhibitors (alirocumab, evolocumab), and ezetim…
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.